Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently
announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has joined
forces with one of the world’s largest tobacco companies to fund the research
and development of Lexaria’s patented DehydraTECHÔ technology to potentially
commercialize a form of oral nicotine delivery. An article discussing the
company reads, “Lexaria’s goal is to create an oral product that eliminates the
need for inhalation and helps curb the smoking habits of consumers. Over 6
million deaths a year worldwide are attributed to nicotine delivery through
smoking. The company believes that its DehydraTECH technology may help the 69
percent of U.S. adult smokers who want to quit move from cigarettes to a safer,
more effective delivery of nicotine (http://ibn.fm/Aps9F). This new partnership allows for
further research and development into oral, reduced-risk nicotine consumer
products.”
To view the full article, visit http://ibn.fm/ndG0V
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10
patents granted in the United States and Australia, and has filed over 50
patent applications worldwide across 10 patent families. Lexaria’s technology
provides more rapid delivery to the bloodstream, as well as important
taste-masking benefits for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
